{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:25:11Z","timestamp":1791573911033,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vaccine.2022.06.065","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T01:09:08Z","timestamp":1660266548000},"page":"5413-5432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2480-9520","authenticated-orcid":false,"given":"Lauri E.","family":"Markowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Drolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayleen M.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lemieux-Mellouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Brotherton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aim\u00e9e R.","family":"Kreimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.06.065_b0005","doi-asserted-by":"crossref","unstructured":"Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine. J Natl Cancer Inst. 2011;103:1444-51.","DOI":"10.1093\/jnci\/djr319"},{"issue":"22","key":"10.1016\/j.vaccine.2022.06.065_b0010","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.vaccine.2022.06.065_b0015","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.06.065_b0020","unstructured":"WHO. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89:465-91."},{"issue":"49","key":"10.1016\/j.vaccine.2022.06.065_b0025","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.06.065_b0030","doi-asserted-by":"crossref","unstructured":"Kreimer AR, Sampson JN, Porras C, Schiller JT, Kemp T, Herrero R, et al. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. J Natl Cancer Inst. 2020;112:1038-46.","DOI":"10.1093\/jnci\/djaa011"},{"issue":"32","key":"10.1016\/j.vaccine.2022.06.065_b0035","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/j.vaccine.2017.12.079","article-title":"Explanations for the high potency of HPV prophylactic vaccines","volume":"36","author":"Schiller","year":"2018","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2022.06.065_b0040","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1016\/j.vaccine.2018.02.076","article-title":"HPV single-dose vaccination: Impact potential, evidence base and further evaluation","volume":"36","author":"Stanley","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.065_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose HPV vaccination among young African women","volume":"1","author":"Barnabas","year":"2022","journal-title":"NEJM Evid"},{"issue":"32","key":"10.1016\/j.vaccine.2022.06.065_b0050","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.vaccine.2018.01.057","article-title":"Human papillomavirus vaccine effectiveness by number of doses: systematic review of data from national immunization programs","volume":"36","author":"Markowitz","year":"2018","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.065_b0055","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1038\/bjc.2014.198","article-title":"Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16\/18 and closely related HPV types","volume":"110","author":"Kavanagh","year":"2014","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.065_b0060","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/bjc.2016.97","article-title":"Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis","volume":"114","author":"Cuschieri","year":"2016","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.065_b0065","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jama.2014.95","article-title":"Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma","volume":"311","author":"Herweijer","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.065_b0070","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/cid\/civ364","article-title":"Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550,000 young girls","volume":"61","author":"Blomberg","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.065_b0075","doi-asserted-by":"crossref","first-page":"e0132404","DOI":"10.1371\/journal.pone.0132404","article-title":"Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: A cohort study","volume":"10","author":"Dominiak-Felden","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.06.065_b0080","doi-asserted-by":"crossref","unstructured":"Perkins RB, Lin M, Wallington SF, Hanchate A. Impact of number of human papillomavirus vaccine doses on genital warts diagnoses among a National Cohort of U.S. Adolescents. Sex Trans Dis. 2017;44:365-70.","DOI":"10.1097\/OLQ.0000000000000615"},{"issue":"25","key":"10.1016\/j.vaccine.2022.06.065_b0085","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.vaccine.2017.04.080","article-title":"Effectiveness of HPV vaccines against genital warts in women from Valencia","volume":"35","author":"Navarro-Illana","year":"2017","journal-title":"Spain Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.065_b0090","doi-asserted-by":"crossref","first-page":"e015021","DOI":"10.1136\/bmjopen-2016-015021","article-title":"Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study","volume":"7","author":"Lamb","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2022.06.065_b0095","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"issue":"mar04 2","key":"10.1016\/j.vaccine.2022.06.065_b0100","doi-asserted-by":"crossref","first-page":"g1458","DOI":"10.1136\/bmj.g1458","article-title":"Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia","volume":"348","author":"Crowe","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.06.065_b0105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pvr.2015.05.005","article-title":"Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia","volume":"1","author":"Brotherton","year":"2015","journal-title":"Papillomavirus Res"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.065_b0110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jamapediatrics.2015.3926","article-title":"Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females","volume":"170","author":"Hofstetter","year":"2016","journal-title":"JAMA Pediatr"},{"issue":"12","key":"10.1016\/j.vaccine.2022.06.065_b0115","doi-asserted-by":"crossref","first-page":"E281","DOI":"10.1503\/cmaj.151528","article-title":"Effect of human papillomavirus vaccination on cervical cancer screening in Alberta","volume":"188","author":"Kim","year":"2016","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.vaccine.2022.06.065_b0120","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.065_b0125","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jadohealth.2018.01.005","article-title":"Epidemiology of any and vaccine-type anogenital human papillomavirus among 13\u201326-year-old young men after HPV vaccine introduction","volume":"63","author":"Chandler","year":"2018","journal-title":"J Adolesc Health"},{"issue":"45","key":"10.1016\/j.vaccine.2022.06.065_b0130","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1016\/j.vaccine.2019.08.052","article-title":"Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction","volume":"37","author":"Widdice","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.06.065_b0135","doi-asserted-by":"crossref","first-page":"e1918571","DOI":"10.1001\/jamanetworkopen.2019.18571","article-title":"Prevalence of Human Papillomavirus Infection by Number of Vaccine Doses Among US Women","volume":"2","author":"Sonawane","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2022.06.065_b0140","doi-asserted-by":"crossref","unstructured":"Markowitz LE, Naleway AL, Klein NP, Lewis RM, Crane B, Querec TD, et al. Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses. J Infect Dis. 2020;221:910-8.","DOI":"10.1093\/infdis\/jiz555"},{"issue":"27","key":"10.1016\/j.vaccine.2022.06.065_b0145","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1016\/j.vaccine.2020.04.041","article-title":"A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination","volume":"38","author":"Batmunkh","year":"2020","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.06.065_b0150","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.06.065_b0155","doi-asserted-by":"crossref","unstructured":"Hoes J, King AJ, Schurink-van 't Klooster TM, Berkhof PJ, Bogaards JA, de Melker HE. Vaccine effectiveness following routine immunization with bivalent HPV vaccine: Protection against incident genital HPV infections from a reduced-dosing schedule. J Infect Dis. 2021. doi: 10.1093\/infdis\/jiab250. Online ahead of print.","DOI":"10.1093\/infdis\/jiab250"},{"key":"10.1016\/j.vaccine.2022.06.065_b0160","doi-asserted-by":"crossref","unstructured":"Hariri S, Schuler MS, Naleway AL, Daley MF, Weinmann S, Crane B, et al. Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States. Am J Epidemiol. 2018;187:298-305.","DOI":"10.1093\/aje\/kwx253"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.065_b0165","first-page":"189","article-title":"The impact of varying numbers of Quadrivalent human papillomavirus vaccine doses on anogenital warts in the united states: a database study","volume":"22","author":"Zeybek","year":"2018","journal-title":"JLGTD"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.065_b0170","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/OLQ.0000000000000742","article-title":"Early evidence of the effectiveness of the human papillomavirus vaccination program against anogenital warts in Manitoba, Canada: a registry cohort study","volume":"45","author":"Willows","year":"2018","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2022.06.065_b0175","doi-asserted-by":"crossref","unstructured":"Baandrup L, Dehlendorff C, Kjaer SK. One-Dose Human Papillomavirus Vaccination and the Risk of Genital Warts: A Danish Nationwide Population-based Study. Clin Infect Dis. 2021;73:e3220-e6.","DOI":"10.1093\/cid\/ciaa1067"},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.065_b0180","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S2352-4642(18)30220-7","article-title":"Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study","volume":"2","author":"Silverberg","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"43","key":"10.1016\/j.vaccine.2022.06.065_b0185","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1016\/j.vaccine.2018.09.011","article-title":"Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions","volume":"36","author":"Dehlendorff","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.065_b0190","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/cid\/ciz239","article-title":"Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: A Danish nationwide cohort study","volume":"70","author":"Verdoodt","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.06.065_b0195","doi-asserted-by":"crossref","first-page":"100177","DOI":"10.1016\/j.pvr.2019.100177","article-title":"Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis","volume":"8","author":"Brotherton","year":"2019","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2022.06.065_b0200","doi-asserted-by":"crossref","unstructured":"Johnson Jones ML, Gargano JW, Powell M, Park IU, Niccolai LM, Bennett NM, et al. Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18. Am J Epidemiol. 2020;189:265-76.","DOI":"10.1093\/aje\/kwz253"},{"issue":"8","key":"10.1016\/j.vaccine.2022.06.065_b0205","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/cncr.32700","article-title":"Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study","volume":"126","author":"Rodriguez","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2022.06.065_b0210","first-page":"72","article-title":"Impact of human papillomavirus vaccination on rates of abnormal cervical cytology and histology in young New Zealand women","volume":"133","author":"Innes","year":"2020","journal-title":"N Z Med J"},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.065_b0215","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/jech-2017-209113","article-title":"The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap","volume":"71","author":"Cameron","year":"2017","journal-title":"J Epidemiol Comm Health"},{"key":"10.1016\/j.vaccine.2022.06.065_b0220","article-title":"Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12\u201313 in Scotland: retrospective population study","volume":"365","author":"Palmer","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.065_b0225","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/1471-0528.16429","article-title":"Human papillomavirus vaccine effectiveness within a cervical cancer screening programme: cohort study","volume":"128","author":"Acuti Martellucci","year":"2021","journal-title":"BJOG"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.065_b0230","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM199802123380703","article-title":"Natural history of cervicovaginal papillomavirus infection in young women","volume":"338","author":"Ho","year":"1998","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.065_b0235","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2022.06.065_b0240","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Eng J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.065_b0245","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","article-title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study","volume":"22","author":"Basu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2022.06.065_b0250","first-page":"261","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022: conclusions and recommendations","volume":"24","year":"2022","journal-title":"WER"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:15:10Z","timestamp":1759403710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22008349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":50,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0264410X22008349"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}